Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 2025-01-22 		5-day change 1st Jan Change
180,500.00 KRW +0.45% Intraday chart for Celltrion, Inc. -2.17% -3.73%
Jan. 14 Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline At the 43Rd Annual J.P. Morgan Healthcare Conference CI
Jan. 09 Celltrion to Unveil Drug Development Plans at JP Morgan Conference MT

Press Releases

Search
See the results
FDA Approves Celltrion's STEQEYMA (Ustekinumab-stba)
Jan. 09
 AQ
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen
Nov. 21
 AQ
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva
Nov. 07
 AQ
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
24-10-16
 AQ
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab
24-10-16
 AQ
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year
24-09-20
 AQ
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents
24-08-16
 AQ
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation
24-06-20
 AQ
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab
24-06-10
 AQ
European Biosimilar Regulatory Update
24-06-10
 AQ
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
24-05-20
 AQ
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
24-05-20
 AQ
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders
24-05-16
 AQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
24-04-22
 AQ
Updates On Aflibercept BPCIA Litigation
24-03-26
 AQ
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.
24-03-20
 AQ
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)
24-03-05
 AQ
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent
24-02-29
 AQ
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47
24-02-29
 AQ
Chugai, Genentech, And Hoffmann-La Roche Dismiss Appeals Of Actemra® Patent IPR Final Written Decisions
24-02-29
 AQ
Updates On Aflibercept BPCIA Litigation
24-02-19
 AQ
Celltrion Launches 80 Mg YUFLYMA (Adalimumab-aaty) In The U.S.
24-02-05
 AQ
PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid
24-01-26
 AQ
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference
24-01-12
 AQ
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation
24-01-11
 AQ
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.
  5. Press Releases